Brief: Codiak Reports Positive Initial Data From Phase 1/2 Trial Of Exosting™ Indicating Evidence Of Tumor Shrinkage

Codiak BioSciences,.

16/11/2021 11:55

Nov 16 (Reuters) - Codiak BioSciences, Inc.  CDAK.O :
    * CODIAK REPORTS POSITIVE INITIAL DATA FOR EXOSTING™ PHASE
1/2
TRIAL INDICATING TOLERABILITY, IMMUNE ACTIVATION, AND EVIDENCE
OF TUMOR SHRINKAGE IN INJECTED AND NON-INJECTED TUMORS IN FIRST
THREE DOSE ESCALATION COHORTS
    * CODIAK BIOSCIENCES, INC. - DATA ON OBJECTIVE RESPONSE RATE
AND
RECOMMENDED PHASE 2 DOSE SELECTION FOR EXPANSION ANTICIPATED 1H
2022
    * CODIAK BIOSCIENCES INC - WITHIN FIRST THREE DOSE COHORTS,
EXOSTING WAS GENERALLY WELL TOLERATED AND NO TREATMENT-RELATED
ADVERSE EVENTS WERE OBSERVED
    * CODIAK BIOSCIENCES, INC. - ENROLLMENT IN COHORTS 4 (6 MCG)
AND 5
(12 MCG) OF EXOSTING TRIAL IS ONGOING

Source text for Eikon:  ID:nGNX38HjQ1 
Further company coverage:  CDAK.O 

 ((Reuters.Briefs@thomsonreuters.com;))